Our Commitment to Growth Hormone Therapy

select your country USA Argentina Australia Austria Belgium Brazil Bulgaria Canada Chile China Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hungary Iraq Ireland Israel Italy Japan Korea (Republic) Latvia Lebanon Lithuania Mexico Netherlands New Zealand Norway Pakistan Poland Portugal Romania Russian Federation Serbia Slovak Republic Slovenia South Africa Spain Sweden Switzerland Syria Taiwan Thailand Turkey Ukraine United Kingdom

• Rate this page
• Send to a friend
• Print

Our
commitment
to GH therapy

1958	The first data are published on the successful GH treatment of a child with GHD. This hormone was extracted from human pituitary glands – pituitary human GH (p-hGH).
1966	The first Danish patients receive p-hGH purified by Novo Nordisk.
1973	p-hGH from Novo Nordisk is registered in Denmark under the name Nanormon®.
1982	Novo Nordisk begins the development of biosynthetic human GH (b-hGH) using recombinant DNA technology – leading to the production of Norditropin® hGH, the successor to Nanormon®.
1988	Norditropin® human growth hormone (hGH) is approved in Europe and Japan for the treatment of GHD children.
1990	Norditropin® hGH is approved for Turner syndrome in Europe.
1990	Novo Nordisk offers injection pen systems.
1995	Norditropin® hGH is approved for GHD in adults in Europe.
1997	Norditropin® hGH is launched in the U.S.
1997	Norditropin® hGH is approved for skeletal dysplasia (Hypochondroplasia and Achondroplasia) in Japan.
1999-2000	Norditropin® hGH in liquid formulation (Norditropin® SimpleXx®) and the NordiPen® injection device are approved in Europe, Japan, and the U.S.
2001-2002	The NordiLet® injection pen is approved.
2003	Norditropin® hGH is approved for SGA in Europe.
2003-2004	The NordiFlex® injection pen is approved in Europe, Japan, and the U.S. Norditropin® hGH is approved for GHDA in the U.S.
2006	The NordiFlex PenMate™ automatic needle-insertion accessory will be launched in Germany, the Netherlands, Sweden, Denmark, Austria, Switzerland, Australia, Japan, and the U.S. in December.